Literature DB >> 2499657

Circulating interleukin 6 during a continuous infusion of tumor necrosis factor and interferon gamma.

P Brouckaert1, D R Spriggs, G Demetri, D W Kufe, W Fiers.   

Abstract

Plasma samples obtained from patients receiving a 24-h continuous infusion of human recombinant (hr)TNF or a combination of two overlapping, 24-h continuous infusions of hrIFN-gamma and hrTNF were analyzed for IL-6 in a sensitive bioassay. A transient appearance of circulating IL-6 was observed with peak levels between 3 and 6 h after the start of the hrTNF infusion. These peak levels correlated quite well with the dose of hrTNF administered (r = 0.86; p less than 0.001). The maximal value observed was 27.5 ng/ml IL-6 in a sample of a patient receiving 545 micrograms/m2 hrTNF. The combination of hrIFN-gamma (200 micrograms/m2) and hrTNF in the infusions resulted in higher IL-6 levels than a comparable dose of hrTNF alone. A maximal value of 23.5 ng/ml IL-6 was observed in a patient receiving 205 micrograms/m2 hrTNF. No IL-6 was found in the plasma of patients during the 12-h infusion with hrIFN-gamma alone, except for two borderline samples.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2499657      PMCID: PMC2189347          DOI: 10.1084/jem.169.6.2257

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  9 in total

1.  In vivo anti-tumour activity of recombinant human and murine TNF, alone and in combination with murine IFN-gamma, on a syngeneic murine melanoma.

Authors:  P G Brouckaert; G G Leroux-Roels; Y Guisez; J Tavernier; W Fiers
Journal:  Int J Cancer       Date:  1986-11-15       Impact factor: 7.396

2.  Multiple actions of interleukin 6 within a cytokine network.

Authors:  G G Wong; S C Clark
Journal:  Immunol Today       Date:  1988-05

3.  Measurement of cell numbers by means of the endogenous enzyme hexosaminidase. Applications to detection of lymphokines and cell surface antigens.

Authors:  U Landegren
Journal:  J Immunol Methods       Date:  1984-03-16       Impact factor: 2.303

4.  Phase I study of 24-hour continuous intravenous infusion of recombinant human tumor necrosis factor.

Authors:  T Steinmetz; M Schaadt; R Gähl; V Schenk; V Diehl; M Pfreundschuh
Journal:  J Biol Response Mod       Date:  1988-10

Review 5.  Cachectin: a hormone that triggers acute shock and chronic cachexia.

Authors:  K J Tracey; S F Lowry; A Cerami
Journal:  J Infect Dis       Date:  1988-03       Impact factor: 5.226

6.  Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study.

Authors:  D R Spriggs; M L Sherman; H Michie; K A Arthur; K Imamura; D Wilmore; E Frei; D W Kufe
Journal:  J Natl Cancer Inst       Date:  1988-09-07       Impact factor: 13.506

7.  Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings.

Authors:  H R Michie; D R Spriggs; K R Manogue; M L Sherman; A Revhaug; S T O'Dwyer; K Arthur; C A Dinarello; A Cerami; S M Wolff
Journal:  Surgery       Date:  1988-08       Impact factor: 3.982

8.  Purification and NH2-terminal amino acid sequence of a T-cell-derived lymphokine with growth factor activity for B-cell hybridomas.

Authors:  J Van Snick; S Cayphas; A Vink; C Uyttenhove; P G Coulie; M R Rubira; R J Simpson
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

9.  Interleukin 1 potentiates the lethal effect of tumor necrosis factor alpha/cachectin in mice.

Authors:  A Waage; T Espevik
Journal:  J Exp Med       Date:  1988-06-01       Impact factor: 14.307

  9 in total
  34 in total

1.  Ablation of TNF-RI/RII expression in Alzheimer's disease mice leads to an unexpected enhancement of pathology: implications for chronic pan-TNF-α suppressive therapeutic strategies in the brain.

Authors:  Sara L Montgomery; Michael A Mastrangelo; Diala Habib; Wade C Narrow; Sara A Knowlden; Terry W Wright; William J Bowers
Journal:  Am J Pathol       Date:  2011-08-09       Impact factor: 4.307

Review 2.  Interleukin-6 and the acute phase response.

Authors:  P C Heinrich; J V Castell; T Andus
Journal:  Biochem J       Date:  1990-02-01       Impact factor: 3.857

Review 3.  How cytokine networks fuel inflammation: Toward a cytokine-based disease taxonomy.

Authors:  Georg Schett; Dirk Elewaut; Iain B McInnes; Jean-Michel Dayer; Markus F Neurath
Journal:  Nat Med       Date:  2013-07       Impact factor: 53.440

4.  Role of tumor necrosis factor alpha, interleukin-1beta, and interleukin-6 in a mouse model of group B streptococcal arthritis.

Authors:  L Tissi; M Puliti; R Barluzzi; G Orefici; C von Hunolstein; F Bistoni
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

Review 5.  Rationale for immunotherapy of renal cell carcinoma.

Authors:  R Heicappell; R Ackermann
Journal:  Urol Res       Date:  1990

6.  Interleukin-6 and renal cell cancer: production, regulation, and growth effects.

Authors:  A S Koo; C Armstrong; B Bochner; T Shimabukuro; C L Tso; J B deKernion; A Belldegrum
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

7.  Anti-tumor necrosis factor modulates anti-CD3-triggered T cell cytokine gene expression in vivo.

Authors:  C Ferran; F Dautry; S Mérite; K Sheehan; R Schreiber; G Grau; J F Bach; L Chatenoud
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

8.  Induction of inflammatory cell infiltration and necrosis in normal mouse skin by the combined treatment of tumor necrosis factor and lithium chloride.

Authors:  R Beyaert; C De Potter; B Vanhaesebroeck; F Van Roy; W Fiers
Journal:  Am J Pathol       Date:  1991-03       Impact factor: 4.307

9.  Interaction of interleukin-6, tumour necrosis factor and interleukin-1 during Listeria infection.

Authors:  Z Liu; R J Simpson; C Cheers
Journal:  Immunology       Date:  1995-08       Impact factor: 7.397

10.  Dysregulation of in vitro cytokine production by monocytes during sepsis.

Authors:  C Munoz; J Carlet; C Fitting; B Misset; J P Blériot; J M Cavaillon
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.